Hospital

FDA-approved Disulfiram can safely reduce anxiety levels in rodents, analysis from the Tokyo University of Sciences and other Japan institutes finds.

The first cases were identified in October 2021 at a children’s hospital in Alabama that admitted 5 children with significant liver injury, including some with acute liver failure.

The booster vaccine candidate includes mutations found in the Beta variant of concern, several of which have been persistent in more recent variants such as the Omicron variant.

The results lead to a possible new therapeutic approach to improve immunotherapy outcomes, including combinations with vitamin E, as well as directly targeting SHP1 in dendritic cells.

DuoBody, for treatment of relapsed/refractory large B-cell lymphoma, demonstrates an overall response rate of 63.1%.

New analysis demonstrates that physical activity improves cognitive health, thus staving off dementia.

In a live virtual symposium at the 2021 ASHP Midyear Clinical Meeting, 2 experts teamed up to highlight the place in therapy and management of oral oncolytics in follicular and marginal zone lymphoma.

32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, offers guidance for female medical researchers who are faced with a declining number of female colleagues in the workforce.

The CIC is a combination of Novavax’s COVID-19 vaccine, NVX-CoV2373, and its quadrivalent influenza vaccine candidate.

The application is based on positive results from the ASCEND phase 3 clinical trial, assessing the efficacy and safety of daprodustat for the treatment of anemia from chronic kidney disease.

Evusheld has been found to significantly reduce the risk of developing symptomatic COVID-19.

The updated efficacy analyses showed that tislelizumab in combination with chemotherapy continued to demonstrate a clinically significant progression-free survival benefit for individuals with recurrent or metastatic nasopharyngeal cancer.

The analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Analysis indicates that quitting provides roughly the same benefit as taking 3 medications together.

The agent is the first oral therapy for this indication.

Investigational CAR T-cell therapy is currently being evaluated in an ongoing dose escalation phase 1 trial to analyze its safety and tolerability in treating non-Hodgkin lymphoma.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses where she sees the classification of lymphoma progressing in the coming years.

Among Black and Latina women with heart failure, negative health outcomes are magnified due to significant health disparities and inequities in the management of the chronic condition.

Fosdenopterin (Nulibry) is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency Type A.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, discusses what biosimilars in the pipeline are expected to launch this year.

Analyses are shared at the American Association for Cancer Research Annual Meeting 2022 in New Orleans, Louisiana.

Sonia Oskouei, PharmD, vice president of biosimilars at Cardinal Health, on the results of Cardinal Health’s assessment of the current biosimilars market published in the 2022 Biosimilars Report.

Although the ISMP created the guidelines for hospitals, they are applicable in other health care settings.

Additionally, the safety profile in DESTINY-Lung01 was consistent with previous clinical trials with no new safety concerns identified.

Asciminib offers a new option for patients harboring the T315I mutation.

Session highlights novel agents that have recently entered, or will imminently enter, into phase 1 clinical trials.

Medicaid expansion implementation was associated with a decrease in the number of uninsured patients from 6.7% pre-expansion to 3.6% post-expansion.

MIS-C is a rare complication of SARS-CoV-2 infection, which is characterized by symptoms such as fever, multiorgan involvement, and documented SARS-CoV-2 exposure.

Elaine Jaffe, MD, National Institutes of Health (NIH) distinguished investigator at the National Cancer Institute at NIH, discusses points of note in the evolution of lymphoma classification during her clinical and investigational research on the subject.